- Home
- PRSO vs ZVSA Comparison
PRSO vs ZVSA Comparison
Compare PRSO & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- ZVSA
- Stock Information
- Founded
- PRSO 2008
- ZVSA 2014
- Country
- PRSO United States
- ZVSA United States
- Employees
- PRSO N/A
- ZVSA N/A
- Industry
- PRSO Semiconductors
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- ZVSA Health Care
- Exchange
- PRSO Nasdaq
- ZVSA Nasdaq
- Market Cap
- PRSO 3.3M
- ZVSA 3.5M
- IPO Year
- PRSO 2001
- ZVSA N/A
- Fundamental
- Price
- PRSO $0.75
- ZVSA $0.61
- Analyst Decision
- PRSO Strong Buy
- ZVSA Strong Buy
- Analyst Count
- PRSO 2
- ZVSA 1
- Target Price
- PRSO $3.38
- ZVSA $240.00
- AVG Volume (30 Days)
- PRSO 66.9K
- ZVSA 426.1K
- Earning Date
- PRSO 03-19-2025
- ZVSA 05-14-2025
- Dividend Yield
- PRSO N/A
- ZVSA N/A
- EPS Growth
- PRSO N/A
- ZVSA N/A
- EPS
- PRSO N/A
- ZVSA N/A
- Revenue
- PRSO $14,573,000.00
- ZVSA N/A
- Revenue This Year
- PRSO $5.08
- ZVSA N/A
- Revenue Next Year
- PRSO $16.15
- ZVSA N/A
- P/E Ratio
- PRSO N/A
- ZVSA N/A
- Revenue Growth
- PRSO 5.99
- ZVSA N/A
- 52 Week Low
- PRSO $0.68
- ZVSA $0.60
- 52 Week High
- PRSO $2.34
- ZVSA $8.05
- Technical
- Relative Strength Index (RSI)
- PRSO 42.07
- ZVSA 26.72
- Support Level
- PRSO $0.68
- ZVSA $0.69
- Resistance Level
- PRSO $0.94
- ZVSA $0.77
- Average True Range (ATR)
- PRSO 0.08
- ZVSA 0.07
- MACD
- PRSO 0.00
- ZVSA -0.00
- Stochastic Oscillator
- PRSO 27.96
- ZVSA 2.19
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.